| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2016018795 |
| Title |
Histone Deacetylase Inhibitors. |
| Abstract |
Provided herein are brain penetrant histone deacetylase (HDAC) inhibitors useful for treating diseases or disorders associated with HDAC. An exemplary HDAC inhibitor provided herein exhibits a brain-to-plama ratio of 20: 1. Pharmaceutical compositions comprising HDAC inhibitors and methods for treating diseases associated with HDAC are also provided. |
| Applicant(s) |
The General Hospital Corporation |
| Representative Drug(s) |
D0DI9S |
Drug Info
|
IC50 > 15000 nM |
[1] |
| Patent ID |
WO2015175813 |
| Title |
Heterocyclic Hydroxamic Acids As Protein Deacetylase Inhibitors and Dual Protein Deacetylase-Protein Kinase Inhibitors and Methods of Use Thereof. |
| Abstract |
The present invention relates to novel hydroxamic acids which are specific histone deacetylase (HDAC) inhibitors and/or TTK/Mpsl kinase inhibitors, including pharmaceutically acceptable salts thereof, which are useful for modulating HDAC and/or TTK/Mpsl kinase activity, pharmaceutical compositions comprising these compounds, and processes for their preparation. |
| Applicant(s) |
The Regents of the University of Colorado, A Body Corporate |
| Representative Drug(s) |
D0BP8I |
Drug Info
|
IC50 > 100000 nM |
[1] |
| Patent ID |
WO2014178606 |
| Title |
Novel Compounds for Selective Histone Deacetylase Inhibitors, and Pharmaceutical Composition Comprising The Same. |
| Abstract |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the preparation of a medicaments comprising the same, a pharmaceutical composition comprising the same, a treatment method using the composition, and a method for preparing novel urea derivatives. The novel urea derivatives as selective histone deacetylase (HDAC) inhibitors are effective for the treatment of histone deacetylase-mediated diseases such as malignant tumors, inflammatory diseases, rheumatoid arthritis, neurodegeneration, etc. |
| Applicant(s) |
Chong Kun Dang Pharmaceutical Corp |
| Representative Drug(s) |
D0LP1K |
Drug Info
|
IC50 = 10300 nM |
[1] |
| Patent ID |
WO2014159210 |
| Title |
Histone Deacetylase Inhibitors and Compositions and Methods of Use Thereof. |
| Abstract |
Provided are certain histone deacetylase (HDAC) inhibitors of Formula I, compositions thereof, and methods of their use. |
| Applicant(s) |
Chdi Foundation, Inc |
| Representative Drug(s) |
D0YN2T |
Drug Info
|
IC50 = 40 nM |
[1] |
| Patent ID |
WO2013041480 |
| Title |
New Thio Derivatives Bearing Lactams As Potent Hdac Inhibitors and Their Uses As Medicaments. |
| Abstract |
The present invention relates to novel amide compounds of Formula (I), and their use as anti-tumoral and pro-apoptotic agents. The invention includes the use of such compounds in medicine, in relation to cancer disease as well as other diseases where an inhibition of HDAC is responsive, and the pharmaceutical composition containing such compounds. |
| Applicant(s) |
Sigma-Tau Industrie Farmaceutiche Riunite Spa |
| Representative Drug(s) |
D07WAT |
Drug Info
|
IC50 = 100 to 500 nM |
[1] |
| United States Patent and Trademark Office (USPTO) |
| Patent ID |
US20170044185 |
| Title |
Preparation of Histone Deacetylase (Hdac) Inhibitors and Methods for Use Thereof. |
| Representative Drug(s) |
D0RA0D |
Drug Info
|
IC50 = 1410 nM |
[1] |
| Patent ID |
US20170015655 |
| Title |
Oxadiazolyl-Substituted Heterocyclic Compounds As Hdac Inhibitors and Their Preparation. |
| Representative Drug(s) |
D0T7OQ |
Drug Info
|
IC50 = 1000 nM |
[1] |
